MENU
CELU
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Celularity (CELU) Ownership - Who owns Celularity?

Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders... Show more

A.I.Advisor
Nov 20, 2026

What Is Celularity (CELU)? Company Overview, Business Model and Market Position

Key Takeaways

  • CELU is the Nasdaq listing for Celularity Inc., a clinical-stage cellular and regenerative medicine company headquartered in Florham Park, New Jersey.
  • The company develops off-the-shelf, placental-derived allogeneic cell therapies targeting cancer, immune and infectious diseases, and aging-related conditions.
  • Its business spans multiple segments, including Cell Therapy, Degenerative Disease, and BioBanking, plus commercial biomaterial products used in surgical and wound care.
  • Celularity monetizes its technology through a proprietary manufacturing platform (IMPACT) as well as licensing and research collaborations with larger pharmaceutical companies.
  • As a small, pre-profitability biotechnology firm, CELU carries elevated clinical, regulatory, and financial risk that investors should weigh carefully.

Introduction

CELU is the ticker for Celularity Inc., a biotechnology company focused on cellular and regenerative medicine. The company is best known for developing "off-the-shelf" cell therapies derived from postpartum human placentas — a source that is generally abundant, ethically obtained, and non-controversial compared with some other cell sources. Investors follow Celularity because its approach to cell therapy, combined with a commercial biomaterials business, represents an attempt to bridge the often long gap between early-stage drug development and near-term revenue generation.

Company Overview and History

Celularity Inc. was founded in 2016 and is headquartered in Florham Park, New Jersey. The company was built around a scientific premise: that the postpartum placenta is a rich, renewable source of cells and biomaterials that can be used to develop therapeutic products at scale. Celularity went public on the Nasdaq through a merger with a special purpose acquisition company (SPAC), GX Acquisition Corp., a route that brought it to public markets with the CELU ticker.

The company is led by founder, Chairman, and Chief Executive Officer Dr. Robert J. Hariri, a physician and scientist who has spent much of his career in cell therapy and regenerative medicine. With a relatively small workforce, Celularity operates as a focused research-and-development organization complemented by a commercial segment.

Business Model and Revenue Sources

Celularity's business model is built around developing and commercializing placental-derived technologies. The company reports its operations across several segments, commonly described as Cell Therapy, Degenerative Disease, and BioBanking. Its revenue comes primarily from commercial products and services rather than from approved therapeutic drugs, reflecting its clinical-stage status.

Key elements of the business include:

  • Cell therapy development: Celularity is advancing allogeneic (derived from a donor rather than the patient) cell therapy candidates, including placental-derived T cells and natural killer (NK) cells for potential use in cancer and other diseases.
  • Commercial biomaterials: The company produces, sells, and licenses products used in surgical and wound care, including brands such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex.
  • BioBanking: Through its LifebankUSA brand, Celularity collects, processes, and stores umbilical cord blood and placental tissue for families following full-term pregnancies.
  • Manufacturing platform: Its IMPACT platform is designed as an integrated process for sourcing, processing, and manufacturing placental-derived products at scale.
  • Licensing and collaborations: The company has pursued partnerships, including a licensing arrangement related to CAR-T products with Sorrento Therapeutics and a research collaboration with Regeneron Pharmaceuticals.

Among its therapeutic programs, Celularity has investigated candidates such as PDA-001 and PDA-002 for potential use in inflammatory, autoimmune, and degenerative conditions, including Crohn's disease, multiple sclerosis, and diabetic peripheral neuropathy.

Market Position and Competitive Landscape

Celularity operates in a competitive field of cell therapy and regenerative medicine, where it contends with larger biotechnology and pharmaceutical companies as well as other clinical-stage developers. Its differentiation rests on its placental platform, which the company positions as a scalable and reproducible source of therapeutic cells and biomaterials. The dual structure of a commercial biomaterials operation alongside a therapeutic pipeline is relatively distinctive among early-stage biotechs, potentially providing a revenue stream while drug candidates advance through clinical trials.

Why Investors Follow CELU

Investors pay attention to CELU primarily because of its exposure to longevity-focused regenerative medicine, a long-term theme centered on treating aging-related and degenerative diseases. The company's off-the-shelf, placental-derived approach could, if successful, offer advantages in manufacturing efficiency and cost compared with personalized (autologous) cell therapies, which must be produced for each individual patient.

The commercial biomaterials and BioBanking segments also give Celularity a financial profile that differs from pure pre-revenue biotechs, potentially offering more stable income alongside its research programs. Additionally, licensing and collaboration agreements with established pharmaceutical companies signal external validation of the underlying technology platform.

Risks and Important Considerations

Investing in Celularity carries significant risks typical of clinical-stage biotechnology. The company's therapeutic candidates must still demonstrate safety and efficacy in clinical trials and secure regulatory approval, a process that is lengthy, expensive, and uncertain. There is no guarantee that its cell therapy programs will advance successfully or generate revenue.

The company also faces operational and financial risks. As a small, pre-profitability firm, it has reported net losses and has periodically faced Nasdaq listing compliance issues related to delayed regulatory filings. Its biomaterials business is subject to competitive pressures and regulatory oversight, while its BioBanking segment depends on consumer demand and reimbursement dynamics. Investors should also note that the company's revenue base remains modest relative to its research ambitions, and its market capitalization is small, which can contribute to elevated share-price volatility and limited liquidity.

AI Screener

For investors seeking to evaluate companies such as Celularity alongside thousands of other opportunities, Tickeron's AI Screener offers a powerful research tool. This AI-powered stock and ETF discovery platform helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies, streamlining the research process in a single, data-driven interface.

Conclusion

Celularity occupies a distinctive niche at the intersection of cell therapy, regenerative medicine, and longevity science. Its placental-derived platform, combined with a commercial biomaterials operation and a BioBanking business, gives it a multi-faceted company overview and financial profile that set it apart from many pure-play biotech peers. At the same time, the company remains an early-stage enterprise with substantial clinical and financial uncertainties. For investors, CELU represents a high-risk, high-reward story tied to the long-term evolution of cell-based medicine.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Profile

Industry
N/A
Address
170 Park Avenue
Phone
+1 908 768-2170
Employees
115
Web
https://www.celularity.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
24.05M
P/E Ratio
-0.23
Total Cash
120K
Projected Growth
0.27
Total Debt
66.76M
Revenue
40.58M
Risk (Beta)
1.55
Dividend Yield
N/A
Total Cash/Share
0.00
Total Debt/Equity
N/A
Revenue/Share
1.04 USD as % of share price
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a blank check company, which focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization

Industry Biotechnology

Industry
N/A
Address
170 Park Avenue
Phone
+1 908 768-2170
Employees
115
Web
https://www.celularity.com
Who owns Celularity? CELU symbol Ownership - Tickeron.com